Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation
November 23, 2020 08:30 ET
|
ARCA biopharma, Inc.
Development addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or notAB201 is the only novel compound being developed for COVID Associated...
ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update
November 02, 2020 08:30 ET
|
ARCA biopharma, Inc.
Initiation of Phase 2b clinical trial evaluating AB201 as a potential treatment for COVID19 anticipated in fourth quarterTopline data from trial anticipated Q2 2021 WESTMINSTER, Colo., Nov. 02,...
ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19
October 07, 2020 08:30 ET
|
ARCA biopharma, Inc.
Initiation of Phase 2b clinical trial anticipated in Q4 2020Trial to enroll approximately 100 patients hospitalized with COVID-19Topline data anticipated Q2 2021 WESTMINSTER, Colo., Oct. 07, 2020 ...
ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19
September 21, 2020 08:00 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Sept. 21, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...